



Curriculum Vitae

Personal information **Helena Faust**

Work experience

1. Employer: Medical Products Agency
 - Start date: 032019
 - End date:
 - Position: Clinical Assessor
 - Activities: Prophylactic and therapeutic vaccine evaluation, Efficacy and Safety. Clinical efficacy assessor in Rapporteurs teams for licensing Hepatitis B vaccine Heplisav B and Biontech/Pfizer SARS_COV_2 vaccine Comirnaty in EU. Clinical assessor in multinational team with NL for Nuvaxovid XBB 1.5 variant Covid-19 vaccine. Clinical assessor in Rapporteurs team for licensing Capvaxive and Papzimeos.
 - Country: Sweden
2. Employer: Karolinska Institutet
 - Start date: 022015
 - End date: 032019
 - Position: post_ doctoral fellow
 - Activities: Research, project management, supervision and teaching. Human Papillomavirus seroepidemiology and vaccinology as main topic.
 - Country: Sweden
3. Employer: Lunds University
 - Start date: 032013
 - End date: 122013
 - Position: Laboratory Scientist
 - Activities: Research. Human papillomavirus caused head and neck_cancers as main subject.
 - Country: Sweden
4. Employer: Lunds University
 - Start date: 102007
 - End date: 122012
 - Position: Doctoral candidate
 - Activities: Research. Development of high_throughput virus serology method, Human papillomavirus and polyomavirus seroepidemiology.
 - Country: Sweden
5. Employer: University of Helsinki
 - Start date: 102006
 - End date: 092007
 - Position: Doctoral candidate
 - Activities: Angiogenesis and stem cell research.
 - Country: Finland
6. Employer: Celecure AS
 - Start date: 032006
 - End date: 092006
 - Position: biotechnology researcher
 - Activities: anti_tumor therapeutics development
 - Country: Estonia
7. Employer: VTT Biotechnology Espoo
 - Start date: 092005
 - End date: 022006
 - Position: biotechnology industry trainee
 - Activities: system biology and metabolic engineering
 - Country: Finland

Education and training

1. Subject: Uppsala University
 - Start date: 092024
 - End date: 012025
 - Qualification: Pharmacology
 - Organisation: Basic course, 15 hp (one full_ termin with 50% activity)
 - Country: Sweden
2. Subject: Uppsala University
 - Start date: 092018
 - End date: 022019
 - Qualification: Clinical Drug Development
 - Organisation: Clinical Drug developments phases, clinical trials etc. 30 hp (one full_ termin with 100% activity)
 - Country: Sweden
3. Subject: Karolinska Institutet
 - Start date: 092018
 - End date: 022019
 - Qualification: Quality and quality development
 - Organisation: Quality control and development. 7.5 hp.
 - Country: Sweden
4. Subject: Lunds University

- Start date: 032008
 - End date: 122012
 - Qualification: Ph D Medical Microbiology
 - Organisation: Research education.
 - Country: Sweden
5. Subject: University of Tartu
- Start date: 092003
 - End date: 062005
 - Qualification: M Sc molecular biology
 - Organisation: Virology, cell and molecular biology, genetics etc.
 - Country: Estonia
6. Subject: University of Tartu
- Start date: 091999
 - End date: 062003
 - Qualification: B Sc molecular biology
 - Organisation: Biology including ecology, botanics, zoology, physiology, human anatomy, molecular biology, microbiology etc.
 - Country: Estonia

Additional information

Publications

1. Human papillomavirus seroprevalence in pregnant women following gender_neutral and girls_only vaccination programs in Finland: A cross_sectional cohort analysis following a cluster randomized trial. Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, Surcel HM, Faust H, Dillner J, Lehtinen M. *PLoS Med.* 2021 Jun 7; 2. Sustained Cross_Reactive Antibody Responses After Human Papillomavirus Vaccinations: Up To 12 Years Follow_Up In The Finnish Maternity Cohort. Kann H, Lehtinen M, Eriksson T, Surcel HM, Dillner J, Faust H. *J Infect Dis.* 2020 Oct 3; *jiaa617*. doi: 10.1093/infdis/jiaa617 3. Long_term follow_up of human papillomavirus type replacement among young pregnant Finnish females before and after a community_randomised HPV vaccination trial with moderate coverage. Gray P, Kann H, Pimenoff VN, Adhikari I, Eriksson T, Surcel HM, Vänskä S, Dillner J, Faust H, Lehtinen M. *Int J Cancer.* 2020 Dec 15; *147(12):3511_3522*. doi: 10.1002/ijc.33169. Epub 2020 Jul 7. 4. Human papillomavirus seroprevalence and seroconversion among men living with HIV: Cohort study in South Africa. Chikandiwa A, Faust H, Chersich MF, Mayaud P, Dillner J, Delany_Moretlwe S. *J Acquir Immune Defic Syndr.* 2020 Feb 14. doi: 10.1097/QAI.0000000000002328. [Epub ahead of print] 5. Human papillomavirus types in cervical dysplasia among young HPV_vaccinated women: Population_based nested case_control study. Kann H, Hortlund M, Eklund C, Dillner J, Faust H. *Int J Cancer.* 2019 Dec 23. doi: 10.1002/ijc.32848. 6. Long_Term Antibody Response to Human Papillomavirus Vaccines: up to 12 Years Follow_Up in the Finnish Maternity Cohort. Artemchuk H, Eriksson T, Poljak M, Surcel HM, Dillner J, Lehtinen M, Faust H. *J Infect Dis.* 2018 Sep 18. doi: 10.1093/infdis/jiy545. 7. Seropositivity to multiple anogenital HPV types is associated with current anogenital HPV infection, abnormal cytology and seropositivity for non_genital HPV. Faust H, Artemchuk H, Ostrbenk A, Triglav T, Poljak M, Dillner J. *J Infect Dis.* 2018 Sep 7. doi: 10.1093/infdis/jiy523. 8. Human papillomavirus (HPV) serology among women living with HIV: Type_specific seroprevalence, seroconversion and risk of cervical_re_infection. Kelly H, Faust H, Chikandiwa A, Ngou J, Helen A Weiss, Segondy M, Dillner J, Delany_Moretlwe S, Mayaud P. *J Infect Dis* Volume 218, Issue 6, 14 August 2018, Pages 927–936; doi: 10.1093/infdis/jiy252 9. Seroprevalences for 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure. Artemchuk H, Triglav T, Ostrbenk A, Poljak M, Dillner J, Faust H. *J Infect Dis.* 2018 Feb 26. doi: 10.1093/infdis/jiy107 10. Effect of naturally acquired type_specific serum antibodies against human papillomavirus type 16 infection. Triglav T, Artemchuk H, Ostrbenk A, Elfstrom KM, Faust H, Poljak M, Dillner J. *J Clin Virol.* 2017 May; *90:64_69*; doi: 10.1016/j.jcv.2017.03.002 11. Effectiveness of HPV vaccination in women reaching screening age in Italy. Carozzi F.M., Ocello C, Burroni E, Faust H, Zappa M, Paci E, Iossa A, Bonanni P, Confortini M, Sani C. *J Clin Virol.* 2016 Nov; *84:74_81*. doi: 10.1016/j.jcv.2016.09.011 12. Prevalence of HPV types, viral load and physical status of HPV16 in head and neck squamous cell carcinoma from the South Swedish Health Care Region. Faust H, Eldenhed Alwan E, Roslin A, Wennerberg J, Forslund O. *J Gen Virol.* 2016 Nov; *97(11):2949_2956*. doi: 10.1099/jgv.0.000611 13. Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. Faust H, Eklund C, Sukvirach S, Ngamkham J, Dillner J. *J Clin Virol.* 2016 May; *78:89_92*. doi: 10.1016/j.jcv.2016.03.014 14. Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case_Control Study. Faust H, Andersson K, Luostarinen T, Gislefoss RE, Dillner J. *Cancer Epidemiol Biomarkers Prev.* 2016 Apr; *25(4):721_4*. doi: 10.1158/1055_9965.EPI_15_1290. 15. Human Papillomavirus neutralizing and cross_reactive antibodies induced in HIV_positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, Østergaard L, Tolstrup M, Dillner J. *Vaccine.* 2016 Mar 18; *34(13):1559_65*. doi: 10.1016/j.vaccine.2016.02.019. 16. Establishment and characterization of a human papillomavirus type 16_positive tonsillar carcinoma xenograft in BALB/c nude mice. Letsolo BT, Faust H, Ekblad L, Wennerberg J, Forslund O. *Head Neck.* 2016 Mar; *38(3):417_25*. doi: 10.1002/hed.23918. 17. Pre_vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population_based Slovenian cervical screening program. Učakar V, Jelen MM, Faust H, Poljak M, Dillner J, Klavs I. *Vaccine.* 2013 Oct 9; *31(43):4935_9*. doi: 10.1016/j.vaccine.2013.08.038. 18. Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma. Faust H, Andersson K, Ekström J, Hortlund M, Robsahm TE, Dillner J. *Int J Cancer.* 2014 Feb 15; *134(4):844_8*. doi: 10.1002/ijc.28419. 19. Unbiased approach for virus detection in skin lesions. Bzhalava D, Johansson H, Ekström J, Faust H, Möller B, Eklund C, Nordin P, Stenquist B, Paoli J, Persson B, Forslund O, Dillner J. *PLoS One.* 2013 Jun 28; *8(6):e65953*. doi: 10.1371/journal.pone.0065953. 20. Efficacy of RG1_VLP vaccination against infections with genital and cutaneous human papillomaviruses. Schellenbacher C, Kwak K, Fink D, Shafti_Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R. *J Invest Dermatol.* 2013 Dec; *133(12):2706_13*. doi: 10.1038/jid.2013.253. 21. Mutations in human papillomavirus type 16 L1 hypervariable surface_exposed loops affect L2 binding and DNA encapsidation. Faust H, Dillner J. *J Gen Virol.* 2013 Aug; *94(Pt 8):1841_9*. doi: 10.1099/vir.0.054205_0. 22. Pseudovirion_binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. Faust H, Andersson K, Forslund O, Dillner J. *J Gen Virol.* 2013 May; *94(Pt 5):1096_103*. doi: 10.1099/vir.0.048561_0. 23. Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. Faust H, Jelen MM, Poljak M, Klavs I, Učakar V, Dillner J. *J Clin Virol.* 2013 Apr; *56(4):336_41*. doi: 10.1016/j.jcv.2012.12.004. 24. Phylogenetically diverse TT virus viremia among pregnant women. Bzhalava D, Ekström J, Lysholm F, Hultin E, Faust H, Persson B, Lehtinen M, de Villiers EM, Dillner J. *Virology.* 2012 Oct 25; *432(2):427_34*. doi: 10.1016/j.virol.2012.06.022. Epub 2012 Jul 21. 25. Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Bissett SL, Wilkinson D, Tettmar KI, Jones N, Stanford E, Panicker G, Faust H, Borrow R, Soldan K, Unger ER, Dillner J, Minor P, Beddows S. *Clin Vaccine Immunol.* 2012 Mar; *19(3):449_51*. doi: 10.1128/CI.05641_11. Epub 2012 Jan 25. 26. Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin. Faust H, Pastrana DV, Buck CB, Dillner J, Ekström J. *J Infect Dis.* 2011 Apr 15; *203(8):1096_100*. doi: 10.1093/infdis/jiq173. 27. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin_coated beads. Faust H, Knekt P, Forslund O, Dillner J. *J Gen Virol.* 2010 Jul; *91(Pt 7):1840_8*. doi: 10.1099/vir.0.019349_0. Epub 2010 Feb 24. 28. Generation and characterization of a single_chain Fv antibody against G, a hedgehog signaling pathway transcription factor. Laht S, Meerits K, Altroff H, Faust H, Tsaney R, Kogerman P, Järvekülg L, Paalme V, Valkna A, Timmusk S. *Hybridoma (Larchmt).* 2008 Jun; *27(3):167_74*. doi: 10.1089/hyb.2008.0004. BOOK CHAPTER Viruses and Human Cancer 2014 (Springer) Merkel Cell Polyomavirus: Epidemiology and Clinical Features of Related Cancer Faust H, and Dillner J. ISBN 978_1_4939_0870_7 PH.D. THESIS Pesudovirions in the Study of Papilloma_ and Polyomaviruses Faust H. Lund University, 2012, ISBN 978_91_87189_68_5

Projects

Memberships

Other Relevant Information